Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR/Cas correction of muscular dystrophies.

Experimental cell research - 1 Nov 2021

Zhang Yu, Nishiyama Takahiko, Olson Eric N, Bassel-Duby Rhonda

Abstract excerpt

Muscular dystrophies are a heterogeneous group of monogenic neuromuscular disorders which lead to progressive muscle loss and degeneration of the musculoskeletal system. The genetic causes of muscular dystrophies are well characterized, but no effective treatments have been developed so far. The discovery and application of the CRISPR/Cas system for genome editing offers a new path for disease treatment with the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR-Cas Systems
Share to Disease Models, Animal
Share to Dystrophin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Editing

Share to Genetic Therapy

Share to Muscular Dystrophy, Duchenne

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 34571006
DOI: 10.1016/j.yexcr.2021.112844
PMCID: PMC8530959

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR/Cas correction of muscular dystrophies.PMID 34571006Read ↗

Correction of muscular dystrophies by CRISPR gene editing.Semantic proximity Read ↗

Methods of CRISPR/Cas9 Exon Skipping for Duchenne Muscular DystrophySemantic proximity Read ↗

CRISPR technologies for the treatment of Duchenne muscular dystrophy.Semantic proximity Read ↗

CRISPR Therapeutics for Duchenne Muscular DystrophySemantic proximity Read ↗

Making gene editing a therapeutic realitySemantic proximity Read ↗

Genome Editing of Monogenic Neuromuscular DiseasesSemantic proximity Read ↗

Role of CRISPR/Cas9 in the treatment of Duchenne muscular dystrophy and its delivery strategies.Semantic proximity Read ↗

Gene Editing for Duchenne Muscular Dystrophy: From Experimental Models to Emerging TherapiesSemantic proximity Read ↗

Precision rewriting of muscle genetics: therapeutic horizons of base and prime editing in skeletal muscle disorders.Semantic proximity Read ↗

Neuromuscular disease: CRISPR/Cas9 gene-editing platform corrects mutations associated with Duchenne muscular dystrophy.Semantic proximity Read ↗

CRISPR-Generated Animal Models of Duchenne Muscular DystrophySemantic proximity Read ↗

Duchenne muscular dystrophy: an updated review of common available therapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.